Pila Pharma

PILA PHARMA: REGULATORY APPROVAL RECEIVED TO CONDUCT PP-CT04, A 12-WEEK TRIAL EXPLORING THE SAFETY AND EFFICACY OF XEN-D0501 IN PEOPLE LIVING WITH OBESITY

PILA PHARMA AB (publ) (FN STO: PILA), a clinical stage biotech company pioneering development of an oral TRPV1-antagonist as a potential first-in-class treatment for obesity and diabetes, announces it has received regulatory approval from the European Medicines Agency, to conduct PP-CT04, a two-part, randomised, double-blind, placebo-controlled, parallel-group, 12‐week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.

PILA PHARMA: CHAIRMAN DORTE X. GRAM REPORT SALE/PURCHASE TRANSACTION BETWEEN OWN CONTROLLED COMPANIES

PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, announces that a share purchase agreement was made between entities controlled by Dorte X. Gram, Chairman of the Board of PILA PHARMA AB.

KOMMUNIKÉ FRÅN PILA PHARMA’S ÅRSSTÄMMA 2026

PILA PHARMA AB (publ) höll idag, tisdagen den 19 maj 2026, årsstämma i bolagets lokaler på Norra Vallgatan 72 i Malmö. Till ordförande för årsstämman valdes advokat Krister Hjelmstedt.

PILA PHARMA: UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT REDEYE DIABETES DAY ON 06 MAY

PILA PHARMA PUBLISHES ITS ANNUAL REPORT FOR 2025

PILA PHARMA: UPDATE TO PRECLINICAL RAT OBESITY STUDIES - LOW EXPOSURE OF XEN-D0501 COULD EXPLAIN LACK OF EFFECT ON BODYWEIGHT

PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that drug exposure in the obese rat studies was very low and plausibly explains the absence of an effect on body weight.

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB

Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdagen den 19 maj 2026, kl. 15.00 i Bolagets lokaler på Norra Vallgatan 72 i Malmö. Registrering till stämman börjar kl. 14.30.

PILA PHARMA CLARIFIES: DECISION TO POSTPONE THE ANNUAL REPORT TO AWAIT CONCLUSION ON PRECLINICAL OBESITY STUDIES

PILA PHARMA POSTPONES THE PUBLICATION OF THE ANNUAL REPORT AND THE ANNUAL GENERAL MEETING

PILA PHARMA: TO PARTICIPATE IN PHARMA PARTNERSHIP CONFERENCE BIO EUROPE SPRING IN LISBON, MARCH 23-25

PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED

PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS